Petmed Express Inc (NASDAQ:PETS)’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, analysts predict that Petmed Express will post $0.92 earnings per share for the current fiscal year. Petmed Express Inc (NASDAQ:PETS) net profit margin is 9.70% and weekly performance is-0.45 %. On last trading day company shares ended up $13.33. Analysts mean target price for the company is $14.00. distance from 50-day simple moving average (SMA50) is 2.56 %.
Alkermes plc (Nasdaq:ALKS) announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia. The randomized, double-blind, active-controlled study will assess ALKS 3831’s efficacy, safety and tolerability in treating schizophrenia in patients with co-occurring alcohol use disorder, compared to olanzapine, an approved and widely used atypical antipsychotic medicine. More than one-third of patients with schizophrenia have a co-occurring alcohol use disorder,1 a population that is commonly excluded from clinical trials and is often undertreated.Alkermes Plc (NASDAQ:ALKS) shares advanced 1.64 % in last trading session and ended the day on $46.56. Gross Margin is 69.40% and its return on assets is1.40 %. quarterly performance is -1.27 %.
Acura Pharmaceuticals (NASDAQ:ACUR) was downgraded by research analysts at MLV & Co from a “buy” rating to a “hold” rating in a report released on Wednesday,TheFlyOnTheWall.com reports. They currently have a $1.00 price objective on the stock, down from their previous price objective of $2.00. MLV & Co‘s price objective suggests a potential downside of 20.63% from the stock’s previous close. Acura Pharmaceuticals, Inc ( NASDAQ:ACUR) shares closed at $1.06, while trading in range of1.02-$1.11. year to date (YTD) performance is -36.53.
Shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML) dropped 6.5% during trading on Monday following a weaker than expected earnings announcement, American Banking News report.Flamel Technologies S.A. (ADR) (NASDAQ:FLML) ended the last trading day at $11.25. Company weekly volatility is calculated as 6.46% and price to cash ratio as 46.28. showed a positive weekly performance of 10.73%.
Columbia Laboratories, Inc (NASDAQ:CBRX) focuses on developing products that utilize its bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. Columbia Laboratories Inc. (NASDAQ:CBRX) net profit margin is 23.50% and weekly performance is 1.83%. On last trading day company shares ended up $6.67. Analysts mean target price for the company is $10.00. distance from 50-day simple moving average (SMA50) is -1.48%.
Leave a Reply